Farshid Dayyani

Farshid Dayyani

Oncology

101 The City Drive South
Building 23
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 113 publications

Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors.

Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors.

Journal: BMC cancer

Published: May 08, 2026

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.

Journal: Future oncology (London, England)

Published: May 04, 2026

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal: Journal of hepatology

Published: April 09, 2026

Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.

Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.

Journal: Journal of vascular and interventional radiology : JVIR

Published: March 28, 2026

Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.

Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 20, 2026

The germline MLH1 c.2054 C>T mutation disrupts DNA mismatch repair and is detectable by digital PCR.

The germline MLH1 c.2054 C>T mutation disrupts DNA mismatch repair and is detectable by digital PCR.

Journal: Cancer letters

Published: February 21, 2026

Regional Therapies Utilized in Treating Unresectable Colorectal Adenocarcinoma with Peritoneal Metastases.

Regional Therapies Utilized in Treating Unresectable Colorectal Adenocarcinoma with Peritoneal Metastases.

Journal: Cancers

Published: February 04, 2026

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

Journal: The oncologist

Published: January 27, 2026

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 19, 2026

Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Journal: Cancers

Published: January 08, 2026

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.

Journal: Journal for immunotherapy of cancer

Published: December 23, 2025

Applying FRESCO trial insights in real-world management of mCRC.

Applying FRESCO trial insights in real-world management of mCRC.

Journal: Clinical advances in hematology & oncology : H&O

Published: November 14, 2025

Showing 1-12 of 113

Last Updated: 09/26/2026